FDA Approved New Basal Cell Carcinoma Treatment
Adults with superficial basal cell carcinoma have a new light-based therapy option to clear skin lesions.
Updated on Oct. 6, 2026 in Cancer
Live Poll
Would you choose a non-surgical light therapy over surgery if diagnosed with skin cancer?
On Sept. 14, 2026, the FDA approved Ameluz gel paired with red-light photodynamic therapy to treat superficial basal cell carcinoma in adults. This non-surgical option offers a new approach for managing this common form of skin cancer.
Why it matters
Basal cell carcinoma requires treatment because it can invade surrounding tissue and cause significant damage if left unchecked. This approval provides a new clinical path for patients seeking to clear lesions while aiming for positive cosmetic outcomes.
A Phase 3 trial of 187 adults found that 66% of patients treated with Ameluz gel and red-light therapy showed complete clearance of their main lesion 12 weeks after treatment. While 89% of treated lesions achieved a good or very good cosmetic result, these findings are recent and long-term durability is still being studied.
The players
FDA
The federal agency responsible for protecting public health by ensuring the safety and efficacy of medical devices and drugs.
The details
The treatment involves applying a gel containing aminolevulinic acid to the lesion and surrounding skin. After a required waiting period, the area is exposed to a red-light lamp, which triggers a chemical reaction to target the cancer cells. Patients may receive up to two treatment cycles, with each cycle consisting of two sessions performed one to two weeks apart. Common side effects include redness, swelling, and stinging or burning at the site.
Timeline
Sept. 14, 2026: The FDA officially approved the use of Ameluz gel for superficial basal cell carcinoma.
12 weeks after treatment: Clinical investigators evaluated patients to confirm lesion clearance.
Health Landscape
This approval marks a significant addition to the FDA's regulatory approval framework for non-surgical oncology interventions, expanding the clinical toolkit beyond traditional surgical excision. It follows the established pattern of integrating light-activated chemical agents into the standard of care for dermatological oncology.
If you have been diagnosed with superficial basal cell carcinoma, it is worth discussing with your doctor whether photodynamic therapy is an appropriate option for your specific case. Be aware that the treatment can cause local reactions such as redness, swelling, and stinging at the site.
The takeaway
This new light-based therapy offers a non-invasive way to clear superficial basal cell carcinoma while maintaining good cosmetic results. Keep a record of any skin changes or new lesions and consult a dermatologist for regular skin cancer screenings.
Further reading
Learn more about evolving options for skin health in our Cancer section.
Source note: This article includes information reported by Curetoday.
Live Poll
Would you choose a non-surgical light therapy over surgery if diagnosed with skin cancer?
